A first in class, first in human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors
A first in class, first in human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors